|
|
Post by sayhey24 on Nov 9, 2021 16:37:17 GMT -5
MannKind Corporation Reports 2021 Third Quarter Financial Results- 3Q 2021 Total Revenues of $22.2 million; +45% vs. 3Q 2020
- 3Q 2021 Afrezza Net Revenue of $9.8 million; +34% vs. 3Q 2020
- $181.1 million of Cash, Cash Equivalents and Investments at September 30, 2021
- Sale-Leaseback of Danbury manufacturing facility closed November 8, 2021
"The net loss for the third quarter of 2021 was $4.4 million, or $0.02 per share, compared to $11.3 million in the third quarter of 2020, or $0.05 per share. The decreased net loss of $6.8 million was primarily due to an increase in Afrezza net revenues and revenues from collaboration and services, as well as a non-cash gain on the extinguishment of the PPP loan, partially offset by an increase in the cost of revenue from collaboration and services and of SG&A expenses. Non-GAAP net loss, adjusted to exclude the PPP loan debt extinguishment was $9.4 million, or $0.04 per share, for the three months ended September 30, 2021 compared to $11.3 million, or $0.05 per share, for the prior year period." When do you think MNKD will be able to post a profit? +.01/share ? Within one year. After 2 quarters of Tyvaso sales MNKD profit will be solid. 3Q2021 projections were a .05 loss so they beat the estimate which is great news. |
|
|
|
Post by lookforgrowth on Nov 9, 2021 16:53:02 GMT -5
Slow but steady as losses continue to decrease. Price has remained reasonably stable compared to the past, even with the delay on Tyvaso DPI. This is encouraging. If we could just got over the ADA prejudice - manipulation, it would be off to the races.
|
|
|
|
Post by sayhey24 on Nov 9, 2021 17:04:40 GMT -5
Slow but steady as losses continue to decrease. Price has remained reasonably stable compared to the past, even with the delay on Tyvaso DPI. This is encouraging. If we could just got over the ADA prejudice - manipulation, it would be off to the races. The ADA is not out friend and never will be. Afrezza is a disruptive technology which would severely impact the ADA's BP gravy train. |
|
|
|
Post by uvula on Nov 9, 2021 17:33:01 GMT -5
Missed the call. Was there any interesting news?
|
|
|
|
Post by peppy on Nov 9, 2021 17:34:30 GMT -5
Missed the call. Was there any interesting news? No words. |
|
|
|
Post by porkini on Nov 9, 2021 17:37:09 GMT -5
Missed the call. Was there any interesting news? No words. So just pitchers? |
|
|
|
Post by esstan2001 on Nov 9, 2021 17:37:57 GMT -5
well technical difficulties, but financially stronger, pipeline loaded up some more, eventually TRe-T and later better Afrezza labels...
|
|
|
|
Post by liane on Nov 9, 2021 17:39:59 GMT -5
$5.05 now. Up is up.
|
|
|
|
Post by blaz on Nov 9, 2021 17:59:48 GMT -5
Vertice/thyquidity co promotion agreement ended
|
|
|
|
Post by peppy on Nov 9, 2021 18:06:15 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Nov 9, 2021 18:17:57 GMT -5
Any thoughts as to why Australian Expansion was Terminated?
|
|
|
|
Post by centralcoastinvestor on Nov 9, 2021 21:18:59 GMT -5
I have read the transcript from todays meeting. There is a lot of great news in the transcript.
1. UTHR will begin buying Tyvaso DPI product from MNKD in the fourth quarter even though FDA approval was not achieved. That should be interesting in terms of new revenue reported in March 2022 for the 4th quarter.
2. In looks like we will get the readout on the Phase 1 Cannabidiol product from Receptor Life Science in the 4th quarter for anxiety. That could be huge.
3. Afrezza sales continue to grow in spite of Covid. Which really is amazing
4. MannKind has $280 million in cash.
5. The product pipeline is so full, they don’t have room for more development
6. Afrezza pediatric phase 3 trial has begun
All I can say is: Wow
|
|
|
|
Post by cjm18 on Nov 9, 2021 21:39:04 GMT -5
I have read the transcript from todays meeting. There is a lot of great news in the transcript. 1. UTHR will begin buying Tyvaso DPI product from MNKD in the fourth quarter even though FDA approval was not achieved. That should be interesting in terms of new revenue reported in March 2022 for the 4th quarter. 2. In looks like we will get the readout on the Phase 1 Cannabidiol product from Receptor Life Science in the 4th quarter for anxiety. That could be huge. 3. Afrezza sales continue to grow in spite of Covid. Which really is amazing 4. MannKind has $280 million in cash. 5. The product pipeline is so full, they don’t have room for more development 6. Afrezza pediatric phase 3 trial has begun All I can say is: Wow It was a wow except afrezza net revenue is down from last quarter. 10m to 9.8m. |
|
|
|
Post by prcgorman2 on Nov 9, 2021 21:46:47 GMT -5
I have read the transcript from todays meeting. There is a lot of great news in the transcript. 1. UTHR will begin buying Tyvaso DPI product from MNKD in the fourth quarter even though FDA approval was not achieved. That should be interesting in terms of new revenue reported in March 2022 for the 4th quarter. 2. In looks like we will get the readout on the Phase 1 Cannabidiol product from Receptor Life Science in the 4th quarter for anxiety. That could be huge. 3. Afrezza sales continue to grow in spite of Covid. Which really is amazing 4. MannKind has $280 million in cash. 5. The product pipeline is so full, they don’t have room for more development 6. Afrezza pediatric phase 3 trial has begun All I can say is: Wow It was a wow except afrezza net revenue is down from last quarter. 10m to 9.8m. Wow, you were counting on Afrezza revenue increase? |
|
|
|
Post by boca1girl on Nov 9, 2021 23:33:03 GMT -5
Did you all catch Mike’s open invitation to the “secrete” shareholder meeting on Wed., 11/10/21?
Send a note to IR and ask to be included on the call. Questions (2) must be submitted in advance.
|
|
